173 related articles for article (PubMed ID: 31437373)
21. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
[TBL] [Abstract][Full Text] [Related]
22. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.
Svobodová S; Browning J; MacGregor D; Pollara G; Scolyer RA; Murali R; Thompson JF; Deb S; Azad A; Davis ID; Cebon JS
Eur J Cancer; 2011 Feb; 47(3):460-9. PubMed ID: 21115342
[TBL] [Abstract][Full Text] [Related]
23. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers.
Miettinen M; Fernandez M; Franssila K; Gatalica Z; Lasota J; Sarlomo-Rikala M
Am J Surg Pathol; 2001 Feb; 25(2):205-11. PubMed ID: 11176069
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker.
Lade-Keller J; Riber-Hansen R; Guldberg P; Schmidt H; Hamilton-Dutoit SJ; Steiniche T
J Clin Pathol; 2014 Jun; 67(6):520-8. PubMed ID: 24607493
[TBL] [Abstract][Full Text] [Related]
25. Microphthalmia transcription factor analysis in posterior uveal melanomas.
Mouriaux F; Vincent S; Kherrouche Z; Maurage CA; Planque N; Monté D; Labalette P; Saule S
Exp Eye Res; 2003 Jun; 76(6):653-61. PubMed ID: 12742347
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma.
Zhang H; Liu J; Yue D; Gao L; Wang D; Zhang H; Wang C
J Clin Pathol; 2013 Nov; 66(11):937-45. PubMed ID: 23853314
[TBL] [Abstract][Full Text] [Related]
27. Stage-specific prognostic biomarkers in melanoma.
Cheng Y; Lu J; Chen G; Ardekani GS; Rotte A; Martinka M; Xu X; McElwee KJ; Zhang G; Zhou Y
Oncotarget; 2015 Feb; 6(6):4180-9. PubMed ID: 25784655
[TBL] [Abstract][Full Text] [Related]
28. Nuclear morphometry, immunohistochemical staining with Ki-67 antibody and mitotic index in the assessment of proliferative activity and prognosis of primary malignant melanomas of the skin.
Talve LA; Collan YU; Ekfors TO
J Cutan Pathol; 1996 Aug; 23(4):335-43. PubMed ID: 8864921
[TBL] [Abstract][Full Text] [Related]
29. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
[TBL] [Abstract][Full Text] [Related]
30. A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients.
Abdulla M; Laszlo S; Triumf J; Hedström G; Berglund M; Enblad G; Amini RM
Acta Oncol; 2016; 55(9-10):1126-1131. PubMed ID: 27549735
[TBL] [Abstract][Full Text] [Related]
31. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690.
Kashani-Sabet M; Nosrati M; Miller JR; Sagebiel RW; Leong SPL; Lesniak A; Tong S; Lee SJ; Kirkwood JM
Clin Cancer Res; 2017 Nov; 23(22):6888-6892. PubMed ID: 28790109
[No Abstract] [Full Text] [Related]
32. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma.
Hazan C; Melzer K; Panageas KS; Li E; Kamino H; Kopf A; Cordon-Cardo C; Osman I; Polsky D
Cancer; 2002 Aug; 95(3):634-40. PubMed ID: 12209757
[TBL] [Abstract][Full Text] [Related]
33. Microphthalmia transcription factor: a sensitive and specific marker for malignant melanoma in cytologic specimens.
Dorvault CC; Weilbaecher KN; Yee H; Fisher DE; Chiriboga LA; Xu Y; Chhieng DC
Cancer; 2001 Oct; 93(5):337-43. PubMed ID: 11668469
[TBL] [Abstract][Full Text] [Related]
34. Melanoma long non-coding RNA signature predicts prognostic survival and directs clinical risk-specific treatments.
Chen X; Guo W; Xu XJ; Su F; Wang Y; Zhang Y; Wang Q; Zhu L
J Dermatol Sci; 2017 Mar; 85(3):226-234. PubMed ID: 27955882
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer.
Egeland EV; Boye K; Park D; Synnestvedt M; Sauer T; ; Naume B; Borgen E; Mælandsmo GM
Breast Cancer Res Treat; 2017 Feb; 162(1):127-137. PubMed ID: 28058579
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis.
Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Chikhlikar PR; Ghosh N; Trivedi TI
Ann Surg Oncol; 2000 May; 7(4):305-11. PubMed ID: 10819372
[TBL] [Abstract][Full Text] [Related]
37. Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
J Invest Dermatol; 2012 Apr; 132(4):1247-52. PubMed ID: 22297638
[TBL] [Abstract][Full Text] [Related]
38. An immunohistochemical study of NFE2L2, KEAP1 and 8-hydroxy-2'-deoxyguanosine and the EMT markers SNAI2, ZEB1 and TWIST1 in metastatic melanoma.
Hintsala HR; Haapasaari KM; Soini Y; Karihtala P
Histol Histopathol; 2017 Feb; 32(2):129-136. PubMed ID: 27170270
[TBL] [Abstract][Full Text] [Related]
39. [Expression of CD117, MITF and NAT10 and their prognostic values in sinonasal mucosal melanoma].
Han F; Liu HQ; Wang SY
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):931-935. PubMed ID: 30522174
[No Abstract] [Full Text] [Related]
40. High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma.
Nodin B; Fridberg M; Jonsson L; Bergman J; Uhlén M; Jirström K
Diagn Pathol; 2012 Jul; 7():82. PubMed ID: 22805320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
